Introduction to Mirapex ER
Mirapex ER, also known as pramipexole dihydrochloride, is a dopaminergic antiparkinsonism agent used primarily to treat the symptoms of Parkinson's disease (PD) and, in some formulations, restless legs syndrome (RLS)[4].
Indications and Approval
Mirapex ER is approved by the FDA for the treatment of both early and advanced Parkinson's disease. It is available as extended-release tablets, which can be used alone or in combination with levodopa. The drug has shown significant improvement in PD symptoms, as measured by the Unified Parkinson’s Disease Rating Scale (UPDRS)[4].
Market Size and Growth
The global Parkinson's disease market, which includes Mirapex ER, is projected to grow substantially. In 2023, the market was valued at USD 3.6 billion and is expected to reach USD 11.66 billion by 2030, with a Compound Annual Growth Rate (CAGR) of around 14%. North America is anticipated to hold the highest revenue share due to its advanced healthcare infrastructure and high prevalence of Parkinson's disease. The Asia Pacific region is expected to grow at the fastest CAGR due to its large population, increasing awareness of neurological disorders, and improving healthcare infrastructure[3].
Pricing and Cost Analysis
The cost of Mirapex ER varies based on the dosage and quantity of the tablets.
- 0.375 mg: The cost for a 7-tablet supply is around $165.19, with a per-unit price of $23.60. For a 30-tablet supply, the cost is approximately $782.67, with a per-unit price of $26.09[2].
- 0.75 mg: Similar to the 0.375 mg dosage, a 7-tablet supply costs around $165.19, and a 30-tablet supply costs about $782.67[2].
- 1.5 mg: A 7-tablet supply is priced at $165.19, and a 30-tablet supply costs around $760.14[2].
- 2.25 mg, 3 mg, 3.75 mg, and 4.5 mg: For these higher dosages, a 30-tablet supply generally costs around $782.67[2].
Generic and Brand Pricing
A generic version of Mirapex ER is available, which can significantly reduce the cost. For example, the generic pramipexole extended-release tablets can cost as low as $165.36 for 30 tablets, depending on the pharmacy and any available discounts[2].
Discount Programs and Patient Assistance
To make Mirapex ER more affordable, various discount programs and patient assistance options are available. The Drugs.com Discount Card, for instance, can save patients up to 80% on prescription medicines, including Mirapex ER. This card is accepted at most major pharmacies across the U.S.[2].
Adverse Reactions and Safety Profile
While Mirapex ER is generally well-tolerated, it comes with several potential adverse reactions. Common side effects include somnolence (sleepiness), nausea, dizziness, constipation, fatigue, hallucinations, and muscle spasms. Notably, somnolence was reported in 36% of patients with early PD and 15% of patients with advanced PD, highlighting the need for prescribers to monitor patients for drowsiness[1][4].
Clinical Trials and Efficacy
Clinical trials have demonstrated the efficacy of Mirapex ER in improving PD symptoms. In one trial, patients treated with Mirapex ER showed significant improvement in UPDRS scores compared to those on placebo. The safety and tolerability profile of Mirapex ER was similar to that of the immediate-release formulation, Mirapex[4].
Regional Market Dynamics
North America is expected to dominate the market due to its advanced healthcare infrastructure and high prevalence of Parkinson's disease. However, the Asia Pacific region is anticipated to grow rapidly due to its large population, increasing awareness of neurological disorders, and improving healthcare infrastructure[3].
Competitive Landscape
The Parkinson's disease market is competitive, with several drugs and treatment options available. Mirapex ER competes with other dopaminergic agents and combination therapies. The market is also influenced by the availability of generic versions and biosimilars, which can impact pricing and market share[3].
Future Outlook
Given the growing prevalence of Parkinson's disease and the aging population, the demand for effective treatments like Mirapex ER is expected to increase. Advances in healthcare infrastructure and research and development activities, particularly in regions like Asia Pacific, will further drive the market growth.
Key Takeaways
- Market Growth: The global Parkinson's disease market is projected to reach USD 11.66 billion by 2030.
- Pricing: Mirapex ER costs vary by dosage, with a 30-tablet supply generally costing around $782.67.
- Generic Options: Generic versions of Mirapex ER are available, significantly reducing costs.
- Adverse Reactions: Common side effects include somnolence, nausea, and dizziness.
- Efficacy: Clinical trials have shown significant improvement in PD symptoms with Mirapex ER.
- Regional Dynamics: North America dominates the market, but Asia Pacific is expected to grow rapidly.
FAQs
1. What is Mirapex ER used for?
Mirapex ER is used to treat the symptoms of Parkinson's disease, both in early and advanced stages.
2. What are the common side effects of Mirapex ER?
Common side effects include somnolence, nausea, dizziness, constipation, fatigue, and hallucinations.
3. How much does Mirapex ER cost?
The cost of Mirapex ER varies by dosage, but a 30-tablet supply generally costs around $782.67.
4. Is a generic version of Mirapex ER available?
Yes, a generic version of Mirapex ER is available, which can significantly reduce the cost.
5. What regions are expected to drive the growth of the Parkinson's disease market?
North America is expected to dominate the market, while the Asia Pacific region is anticipated to grow rapidly due to its large population and improving healthcare infrastructure.
Sources
- Boehringer Ingelheim, "MIRAPEX ER-US-PI.pdf"
- Drugs.com, "Mirapex ER Prices, Coupons, Copay Cards & Patient Assistance"
- GlobeNewswire, "$11.66 Billion Parkinson's Disease Market Forecast, 2030 by Drug Class, Medical Devices, Devices, Route of Administration, Distribution Channel, and Region"
- Clinical Trials Arena, "Mirapex (Pramipexole Dihydrochloride) for the Treatment of Parkinson's Disease"
- DrugPatentWatch, "Drug prices and trends for PRAMIPEXOLE"
